Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a research report sent to investors on Friday. The firm issued a buy rating and a $14.00 price target on the stock.

ORIC has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, April 21st. The Goldman Sachs Group upgraded Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Friday, May 15th. Wedbush reduced their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 1st. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday. Finally, Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oric Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $18.92.

Oric Pharmaceuticals Trading Up 5.8%

ORIC stock opened at $8.27 on Friday. The company has a market capitalization of $856.11 million, a P/E ratio of -5.74 and a beta of 1.04. The firm has a 50 day simple moving average of $9.03 and a 200-day simple moving average of $10.17. Oric Pharmaceuticals has a twelve month low of $7.23 and a twelve month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, research analysts predict that Oric Pharmaceuticals will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC increased its position in shares of Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in shares of Oric Pharmaceuticals in the 4th quarter worth $19,642,000. Siren L.L.C. lifted its stake in shares of Oric Pharmaceuticals by 197.6% in the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after purchasing an additional 1,990,617 shares during the period. State Street Corp lifted its stake in shares of Oric Pharmaceuticals by 77.1% in the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Oric Pharmaceuticals by 48.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after acquiring an additional 1,525,445 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.